Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Non-interventional, Phase IV Multicentre Study to Assess the Effectiveness, Safety and Tolerability of Elafibranor 80 mg/Day in Participants With Primary Biliary Cholangitis Receiving Treatment in a Real-world Setting.

NCT06447168 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT06447168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06447168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Non-interventional, Phase IV Multicentre Study to Assess the Effectiveness, Safety and Tolerability of Elafibranor 80 mg/Day in Participants With Primary Biliary Cholangitis Receiving Treatment in a Real-world Setting.
Lead sponsor
Ipsen
Phase
Observational
Overall status
Active, not recruiting
Start date
October 14, 2024
Completion date
July 15, 2032
Enrollment
424 (estimated)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cholangitis